Altimmune ALT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's total equity?
- Altimmune (ALT) reported total equity of $283.99M in Q1 2026.
- How has Altimmune's total equity changed year-over-year?
- Altimmune's total equity increased by 99.8% year-over-year, from $142.16M to $283.99M.
- What is the long-term trend for Altimmune's total equity?
- Over 5 years (2020 to 2025), Altimmune's total equity has grown at a -0.1% compound annual growth rate (CAGR), from $225.88M to $224.89M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.